TGF-beta1 gene knockout tumor cell and application of TGF-beta1 gene knockout tumor cell combined immunologic adjuvant in preparation of tumor cell vaccine

By knocking out the TGF-β1 gene in tumor cells and combining with Poly I:C, a highly immunogenic tumor cell vaccine was prepared, which solved the problem of low immunogenicity of tumor cells and achieved effective anti-tumor prevention and treatment. The survival of mice was significantly extended.

CN118879631APending Publication Date: 2024-11-01WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410778252.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-17
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The low immunogenicity of tumor cells and insufficient antigen presentation of tumor cell vaccines limit the application of tumor cell vaccines.

Method used

Highly immunogenic tumor cell vaccines were prepared by knocking out the TGF-β1 gene in tumor cells and combining with the immune adjuvant Poly I:C for prophylactic and therapeutic applications.

Benefits of technology

It significantly improves the immunogenicity of tumor cells, can induce long-term anti-tumor immune memory through subcutaneous injection, prevent tumor occurrence, and significantly inhibit tumor progression and prolong the survival of tumor-bearing mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879631A_ABST
    Figure CN118879631A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of tumor vaccine development, and particularly relates to a TGF-beta1 gene knockout tumor cell and application of the TGF-beta1 gene knockout tumor cell in preparation of a tumor cell vaccine after being combined with an immunologic adjuvant. Aiming at the problems that a tumor cell vaccine is low in immunogenicity and is difficult to induce and generate enough anti-tumor immune response, the invention provides a TGF-beta1 gene knockout tumor cell and application of a combined immunologic adjuvant thereof in preparation of a tumor vaccine. It is found for the first time that the immunogenicity of tumor cells can be improved by knocking out TGF-beta1. It is proved for the first time that TGF-beta1 can be used as a new transformation target of the tumor cell vaccine. After the vaccine prepared by inactivating the TGF-beta1 gene knockout tumor cells is injected into mice, the occurrence of tumors can be prevented. After being combined with an immunologic adjuvant, the tumor cell vaccine can remarkably inhibit the progress of subcutaneous tumors, prolong the lifetime of tumor-bearing mice and induce generation of long-term anti-tumor immune memory, and has potential significance in clinical application of tumor cell vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of tumor vaccine development, and specifically relates to a use of TGF-β1 gene knocked-out tumor cells combined with an immune adjuvant in the preparation of a tumor cell vaccine. Background Art

[0002] Malignant tumors are common and frequently occurring diseases that seriously threaten human health. Immunotherapy and treatment with tumor vaccines have developed rapidly and have become a hot topic in immunotherapy and treatment. Currently, immune checkpoint inhibitor therapy with CTLA-4 and PD-1 / PD-L1 antibodies has improved the clinical outcomes of some patients with highly immunogenic tumors, but most patients still do not respond to treatment or develop drug resistance. Therefore, it is necessary to explore new treatment strategies to improve the efficacy of immunotherapy.

[0003] Tumor cell vaccine is a vaccine made from autologous tumor tissue or allogeneic tumor cells after inactivation. After the tumor cell vaccine is injected into the patient's body, it can theoretically promote antigen presentation and activate the patient's adaptive immune system, thereby achieving the purpose of preventing or inhibiting tumor growth. Generally speaking, it can present a more complete tumor antigen spectrum, including tumor-associated antigens and tumor-specific antigens, thereby stimulating a more effective immune response and reducing the occurrence of tumor escape. However, tumor cells secrete soluble factors that can inhibit immune cells and have low immunogenicity, which limits the application of tumor cell vaccines.

[0004] Transforming growth factor β (TGF-β) is a secreted protein that acts as an immunosuppressive molecule and can reduce the body's anti-tumor immunity and tumor immune surveillance through a variety of direct or indirect mechanisms. There are three highly homologous TGF-β subtypes in mammals, TGF-β1, TGF-β2, and TGF-β3. Among them, TGF-β1 is the most commonly expressed subtype in most human tumor types, and it is most closely related to TGF-β signal activation. There are currently no reports on knocking out TGF-β1 in tumor cells and using it to prepare tumor cell vaccines. Summary of the invention

[0005] The technical problem to be solved by the present invention is that the low immunogenicity of tumor cells and insufficient antigen presentation of tumor cell vaccines limit the application of tumor cell vaccines.

[0006] The technical solution of the present invention to solve the above technical problem is: to provide a use of TGF-β1 gene knocked-out tumor cells in the preparation of tumor cell vaccines.

[0007] Among them, in the above-mentioned use, the tumor cells with TGF-β1 gene knockout need to be inactivated.

[0008] Preferably, in the above use, the inactivation method is irradiation inactivation.

[0009] Furthermore, the irradiation is X-ray irradiation, and the irradiation dose is 60Gy for a single irradiation.

[0010] Among them, in the above-mentioned use, the tumor cell vaccine is a preventive tumor cell vaccine.

[0011] Among them, in the above-mentioned use, the tumor cells include: at least one of melanoma, colorectal cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, gastric cancer, bile duct cancer, gallbladder cancer, esophageal cancer, kidney cancer, pancreatic cancer, prostate cancer or glioblastoma.

[0012] Furthermore, the present invention also provides a use of TGF-β1 gene knockout tumor cells combined with immune adjuvants in the preparation of tumor cell vaccines.

[0013] Wherein, in the above use, the immune adjuvant is Poly I:C immune adjuvant.

[0014] Among them, in the above use, the ratio of the TGF-β1 gene knockout tumor cells to the immune adjuvant is 1×10 6 The cells were mixed with 25 μg Poly I:C.

[0015] Among them, in the above-mentioned use, the tumor cell vaccine is a preventive or therapeutic tumor cell vaccine.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention discovers for the first time that knocking out the TGF-β1 gene of tumor cells can improve the immunogenicity of tumor cells. Therefore, a use of tumor cells with TGF-β1 gene knockout in the preparation of tumor cell vaccines is provided. At the same time, the present invention also finds that tumor cells with TGF-β1 gene knockout combined with immune adjuvant Poly (I:C), through appropriate proportions, can not only prepare preventive vaccines, but also prepare therapeutic tumor cell vaccines. The therapeutic tumor cell vaccine of the present invention can significantly inhibit tumor progression and prolong the survival of tumor-bearing mice after subcutaneous injection. In addition, it solves the defects of existing therapeutic tumor cell vaccine administration routes, such as intracranial in situ administration or intrasplenic injection, which are complex, difficult, and have high treatment risks, and are not conducive to later clinical transformation. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1The figure shows the construction of TGF-β1 knockout tumor cell line; (a) is the Western Blot detection of TGF-β1 expression in tumor cells; (b) is the ELISA detection of TGF-β1 content in cell culture supernatant;

[0019] Figure 2 The figure shows the preparation of TGF-β1 knockout tumor cell vaccine; (a) is CCK8 evaluation of the in vitro proliferation efficiency of TGF-β1 knockout tumor cells after different irradiation doses; (b) is a statistical chart of long-term observation of in vivo growth of tumor cells after 60Gy irradiation;

[0020] Figure 3 The figure shows the use of TGF-β1 knocked-out tumor cells; (a) is a schematic diagram of the preventive model construction strategy of TGF-β1 knocked-out tumor cell vaccine; (b) is a statistical diagram of the tumor growth curves of each group in the preventive model;

[0021] Figure 4 The figure shows the exploration of the optimal dose of PolyIC to promote the anti-tumor effect of TGF-β1 knockout tumor cell vaccine; (a) is a schematic diagram of the combined treatment of different doses of PolyIC and C26 TGF-β1KO; (b) is a statistical diagram of the tumor volume of each group on the 20th day after tumor inoculation, n=4;

[0022] Figure 5 The figure shows the use of TGF-β1 knockout tumor cell vaccine combined with immune adjuvant Poly(I:C); wherein (a) is a tumor growth curve in a subcutaneous heterotopic transplant tumor model, n=8; (b) is a tumor growth curve of a single mouse in each treatment group in a subcutaneous heterotopic transplant tumor model, n=8; (c) is a bright field photograph of the lung tissue of mice in each treatment group in a lung metastasis model; (d) is a statistical graph of the number of lung metastasis nodules in each treatment group in a lung metastasis model.

[0023] Figure 6 Shown is a diagram of the biosafety evaluation of TGF-β1 knockout tumor cell vaccine combined with immune adjuvant Poly(I:C) therapy. DETAILED DESCRIPTION

[0024] Tumor cells show poor immunogenicity due to secretion of soluble factors that can inhibit immune cells, and are often difficult to induce a strong immune response. The present invention reduces the immunosuppression of tumor cells and improves the immunogenicity of tumor cells by knocking out TGF-β1. The vaccine prepared by inactivating tumor cells with TGF-β1 gene knockout can prevent the occurrence of tumors after being injected into mice.

[0025] Most of the current preclinical studies involve therapeutic tumor cell vaccine administration routes, such as intracranial in situ administration or intrasplenic injection, which are complex, difficult, and have high treatment risks, which are not conducive to later clinical transformation. The present invention combines the immune adjuvant Poly (I: C) with the TGF-β1 gene knockout tumor cell vaccine, which can significantly inhibit tumor progression and prolong the survival of tumor-bearing mice after subcutaneous injection. The present invention has potential significance for the clinical application of tumor cell vaccines.

[0026] In the present invention, we constructed tumor cells with TGF-β1 knockout, and prepared them into tumor cell vaccines after irradiation inactivation. Subcutaneous immunization of mice can induce long-term anti-tumor immune memory and prevent the occurrence of tumors. In addition, the combination of TGF-β1 knockout tumor cell vaccine and immune adjuvant Poly (I: C) treatment can promote antigen presentation, activate the adaptive immune system of mice, inhibit tumor progression, and prolong the survival of tumor-bearing mice. The vaccine preparation and treatment strategy involved in this invention provide a certain basis for the research and development of tumor cell vaccines.

[0027] The present invention is described in detail below through specific embodiments in conjunction with the accompanying drawings. In the following examples, any specific experimental conditions not specified are based on conventional conditions well known to those skilled in the art.

[0028] Example 1 Construction of TGF-β1 knockout tumor cells

[0029] The specific operations are as follows:

[0030] 1. Construction of CRISPR-Cas9 targeting vector:

[0031] The mouse genome TGF-β1 sequence was obtained through NCBI (https: / / www.ncbi.nlm.nih.gov / ) and the online CRISPR / Cas9 design tool website was used at http: / / crispr.dbcls.jp / .

[0032] Mouse gRNA sequence information is as follows:

[0033] Forward sequence (SEQ ID NO: 1): CACCTGTACAACAGCACCCGCGACCGG;

[0034] Reverse sequence (SEQ ID NO: 2): AAACCCGGTCGCGGGTGCTGTTGTACA.

[0035] Through enzyme digestion, gRNA phosphorylation and annealing reaction, ligation, transformation and other experimental steps, the Cas9 lentiviral vector LentiCRISPR v2-puro-TGF-β1 marked with puromycin selection was obtained by sequencing and comparison.

[0036] 2. Lentivirus packaging and concentration:

[0037] (1) When the 293T cell density reaches 90%, start preparing the transfection complex;

[0038] (2) Replace the culture medium of 293T cells with DMEM basal medium preheated at 37°C;

[0039] (3) Take a 1.5 ml EP tube, add 500 μL of Opti-MEM medium, and add lentiviral packaging plasmid 6 μg pMD2.G, 12 μg pxPAX2 and 12 μg target plasmid in sequence;

[0040] (4) Take another 1.5 ml EP tube, add 500 μL of Opti-MEM medium and 75 μL of PEI solution;

[0041] (5) Mix the solutions in the two EP tubes to prepare the transfection complex, mix thoroughly, and let stand at room temperature for 20 min;

[0042] (6) Gently but evenly add the above transfection complex to the culture dish of 293T cells and gently mix;

[0043] (7) After placing the cell culture dish in a 37°C incubator for 6 h, the culture medium was replaced with 37°C preheated DMEM and cultured in the incubator for another 24 h;

[0044] (8) The culture supernatant of the virus particles was collected for the first time, filtered through a 0.22 μm filter to remove cell debris and bacteria, and the virus supernatant was placed in a 4°C refrigerator and gently added with 10% FBS-DMEM for 24 h;

[0045] (9) The supernatant of the virus particles collected for the second time also needs to be filtered through a 0.22 μm filter to remove cell debris and bacteria.

[0046] (10) The previously collected viral supernatant was subjected to ultracentrifugation to concentrate the virus.

[0047] 3. Lentivirus infection of tumor cells:

[0048] (1) The tumor cells to be infected are plated in advance in a cell well plate. When the cell confluence reaches 50%, lentiviral infection is performed;

[0049] (2) Carefully remove the tumor cell culture supernatant and add DMEM cell culture medium containing lentivirus;

[0050] (3) After thorough mixing, place in a cell culture incubator for continued culture.

[0051] 4. Puromycin screening and monoclonal screening of TGF-β1 knockout tumor cells:

[0052] (1) The optimal concentration for positive cell screening was explored in advance by setting a puromycin concentration gradient (final concentrations of 1, 4, 6, 8, 10, 12, 14, and 16 μg / mL);

[0053] (2) When the cell confluence reaches about 70%, puromycin selection is performed;

[0054] (3) After 48 h of puromycin selection, cells were passaged or the medium was changed;

[0055] (4) The next day, digest the cells, add the cell suspension to a 15 mL BD tube, and count the cells;

[0056] (5) After dilution again, take 100 cells, add them to 10 ml of culture medium, mix thoroughly, and add 100 μL / well to a 96-well plate;

[0057] (6) After the cells have grown into single clones, DNA is extracted and sequenced from the positive clones to verify gene knockout.

[0058] Western Blot was used to detect the expression of TGF-β1 in tumor cells. Figure 1 As shown: Figure 1 Figure a shows that compared with the control C26 cells, the expression of TGF-β1 protein in the transformed cell line was significantly reduced, which is consistent with the ELISA results in Figure 1b. It can be seen that TGF-β1 knockout tumor cells were successfully constructed in this experiment.

[0059] Example 2 Preparation of TGF-β1 knockout tumor cell vaccine

[0060] First, the optimal radiation dose for tumor cells was explored: C26 tumor cells were irradiated with a gradient of 0-100Gy, then cultured and the cell proliferation rate at different time points was measured using CCK-8; cell morphology was observed under an inverted microscope, and it was found that the optimal radiation dose for vaccine preparation was 60Gy.

[0061] After determining the optimal radiation dose for vaccine preparation, the tumor cells are irradiated to prepare the tumor cell vaccine. The specific operation is as follows:

[0062] (1) Observe TGF-β1 knockout tumor cells under a microscope and select tumor cells in the logarithmic growth phase for vaccine immunization;

[0063] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0064] (3) Centrifuge at 1200 rpm for 3 min to collect cells;

[0065] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0066] (5) Resuspend the cells in serum-free medium and count the cells using 0.4% trypan blue staining solution to adjust the cell concentration to 1×10 6 cells / ml;

[0067] (6) Tumor cells were irradiated with a dose of 60 Gy to prepare vaccines.

[0068] The experimental results are as follows Figure 2 As shown in the figure, it can be seen that under 60Gy irradiation, the growth rate of tumor cells was significantly inhibited ( Figure 2 a). In addition, we will 5 After irradiation with a dose of 60 Gy, the tumor cells were inoculated subcutaneously in vivo. The tumor growth was monitored continuously for 20 days. The tumors in the unirradiated control group grew normally to 1500 mm 3 However, no tumor was observed in the 60 Gy irradiation group ( Figure 2 b). It can be seen that the irradiated tumor cells have been inactivated and can be used to prepare tumor cell vaccines.

[0069] Example 3 Use of TGF-β1 knockout tumor cells in the preparation of preventive tumor vaccines

[0070] This study explored the use of TGF-β1 knockout tumor cell vaccines and constructed a preventive vaccine model. Mice were immunized subcutaneously with 1×10 6 After 60 Gy irradiation, the cells were subcutaneously injected into mice, once every three days, for a total of two immunizations. One week later, tumor cells were subcutaneously inoculated, and the growth status and tumor load of the mice were subsequently recorded.

[0071] The specific operations are as follows:

[0072] 1. Preparation of preventive tumor cell vaccines

[0073] (1) Observe the cells under a microscope and select tumor cells in the logarithmic growth phase for vaccine immunization;

[0074] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0075] (3) Collect cells by centrifugation at 1200 rpm for 3 min;

[0076] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0077] (5) Resuspend the cells in serum-free medium and count the cells using 0.4% trypan blue staining solution to adjust the cell concentration to 1×10 6 cells / ml;

[0078] (6) Irradiate tumor cells at a dose of 60 Gy to prepare preventive tumor vaccines for use.

[0079] 2. Vaccination of mice with preventive tumor vaccines

[0080] (1) Observe the cells under a microscope, especially the cell morphology and background, to ensure that the cell state is suitable for inoculation;

[0081] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0082] (3) Collect cells by centrifugation at 1200 rpm for 3 min;

[0083] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0084] (5) Count the cells using 0.4% trypan blue staining solution and prepare the inoculated cells to a concentration of 5 × 10 6 cells / ml, 100 μL was inoculated per mouse.

[0085] (6) Shave the hair around the mouse's legs in advance to facilitate vaccination.

[0086] (7) During inoculation, the inoculation site was gently wiped with 75% ethanol and disinfected before inoculation of tumor cells subcutaneously near the thigh. Each mouse was inoculated with 5×10 cells. 5 cells / 100μL.

[0087] (8) Tumor volume was measured every 3 days. 3 )=(length×width 2 ) / 2.

[0088] The experimental results are as follows Figure 3 As shown in a: In the group containing C26 TGF-β1KO tumor vaccine, the tumor growth of mice was completely inhibited. In contrast, the tumor growth of the PBS group was normal ( Figure 3 b). This indicates that TGF-β1 knockout tumor cells can be used to prepare tumor cell vaccines, which can prevent the occurrence of tumors and have a good preventive anti-tumor protective effect.

[0089] Example 4 Use of TGF-β1 knockout tumor cells combined with immune adjuvant Poly(I:C) in the preparation of therapeutic tumor vaccines

[0090] (I) Exploring the dosage of the immune adjuvant Poly(I:C)

[0091] Different doses of Poly(I:C) were mixed with irradiated C26 tumor cell vaccine and treated according to the strategy in Figure 4a, with subcutaneous injection on the opposite side of the tumor inoculation site, once every three days, for a total of three injections.

[0092] The experimental results are as follows Figure 4 As shown in a: From the 20th day after treatment, the tumor volume statistics of each group showed that at a dose of 25 μg, the tumor growth of mice was most significantly inhibited, and the vaccine had the best therapeutic effect at this time ( Figure 4 b). Therefore, it was concluded that when TGF-β1 knockout tumor cells were combined with immune adjuvant Poly(I:C) to prepare a vaccine, the amount of immune adjuvant Poly(I:C) added was 25 μg.

[0093] (II) Effect of TGF-β1 knockout tumor cells combined with immune adjuvant Poly(I:C) in treating tumors

[0094] 25 μg of PolyIC was mixed with TGF-β1 knockout tumor cell vaccine and injected subcutaneously into mice. Treatment was performed every 3 days for a total of 3 times.

[0095] The specific method is as follows:

[0096] 1. Construction of subcutaneous heterotopic tumor model

[0097] (1) Observe the cells under a microscope, especially the cell morphology and background, to ensure that the cell state is suitable for inoculation;

[0098] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0099] The cells were collected by centrifugation for 3 min;

[0100] (3) Collect cells by centrifugation at 1200 rpm for 3 min;

[0101] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0102] (5) Count the cells using 0.4% trypan blue staining solution and prepare the inoculated cells to a concentration of 5 × 10 6 cells / ml, 100 μL was inoculated per mouse.

[0103] (6) Shave the hair around the mouse's legs in advance to facilitate vaccination.

[0104] (7) During inoculation, the inoculation site was gently wiped with 75% ethanol and disinfected. After that, tumor cells were inoculated subcutaneously near the right thigh. Each mouse was inoculated with 5×10 cells. 5 cells / 100μL.

[0105] (8) Tumor volume was measured every 3 days. 3 )=(length×width 2 ) / 2.

[0106] 2. Construction of lung metastasis tumor model

[0107] (1) Observe the cells under a microscope, especially the cell morphology and background, to ensure that the cell state is suitable for inoculation;

[0108] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0109] (3) Collect cells by centrifugation at 1200 rpm for 3 min;

[0110] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0111] (5) Count the cells using 0.4% trypan blue staining solution and prepare the inoculated cells to a concentration of 5 × 10 6 cells / ml, 100 μL was inoculated per mouse.

[0112] (6) Wipe the mouse tail with alcohol cotton to make it fully congested, and inject 3×10 cells into the tail vein of each mouse. 5 cells / 100μL.

[0113] 3. Vaccine immunization in mice

[0114] (1) Observe the cells under a microscope and select tumor cells in the logarithmic growth phase for vaccine immunization;

[0115] (2) Digest the cells with trypsin and neutralize them with serum-containing DMEM medium after the cells fall off;

[0116] (3) Collect cells by centrifugation at 1200 rpm for 3 min;

[0117] (4) After resuspending the cells in serum-free DMEM medium, centrifuge at 1200 rpm for 3 min. Repeat this process twice to wash away any residual serum components.

[0118] (5) Resuspend the cells in serum-free medium and count the cells using 0.4% trypan blue staining solution. Adjust the cell concentration to 1×10 6 cells / ml;

[0119] (6) 60y irradiation of tumor cells to prepare vaccine and mixed with 25μg PolyIC;

[0120] (7) The drug was administered on the opposite side of the tumor inoculation site, once every 3 days, for a total of 3 treatments.

[0121] The experimental results are as follows Figure 5 As shown: In the subcutaneous heterotopic transplantation tumor model, compared with the PBS group, C26 group, C26 TGF-β1KO group and PolyIC group, the C26 TGF-β1KO+PolyIC treatment group had the best treatment results, and the tumor inhibition rate was 71.6% (compared with the PBS blank control group). Figure 5 a). Compared with other treatment groups, the survival of mice in the C26 TGF-β1KO+PolyIC treatment group was significantly improved. On the 60th day after inoculation, 30% of the mice were still alive ( Figure 5 b). In the lung metastasis model, the lung tissue images show that the lungs of the C26 group and the PolyIC group are covered with very obvious tumor tissue. In contrast, the C26TGF-β1KO cell vaccine treatment group and the C26 TGF-β1KO+PolyIC treatment group have fewer lung metastatic nodules. The C26 TGF-β1KO+PolyIC group has the smallest lung tumor burden in mice ( Figure 5 c, 5d). The above results show that TGF-β1 knockout tumor cells combined with immune adjuvant Poly(I:C) can not only inhibit the growth of mouse heterotopic transplanted tumors and significantly prolong the survival of tumor-bearing mice, but also inhibit tumor lung metastasis.

[0122] Example 5 Biosafety Evaluation

[0123] Mice were sacrificed after treatment, and pathological analysis of the heart, liver, spleen, lung, and kidney was performed.

[0124] The specific method is as follows:

[0125] (1) Place paraffin sections of the heart, liver, spleen, lung, and kidney in an oven at 65-70°C for 1-2 h;

[0126] (2) Dewaxing with xylene twice, 5 min each time; dewaxing with 100%, 95%, 85%, and 75% ethanol for 3 min each;

[0127] (3) The sections were then rinsed in PBS twice, 3 min each time;

[0128] (4) Hematoxylin staining, room temperature, staining for about 3 minutes;

[0129] (5) Rinse with water until blue, 5 min;

[0130] (6) Eosin staining for 20 seconds; observe the staining under a microscope;

[0131] (7) After the slides are naturally dried, they are sealed with neutral gum.

[0132] The results are as follows Figure 6 As shown, it can be seen that the tumor cell vaccine of the present invention will not cause tissue lesions and significant tissue damage after treatment, and has good biosafety.

Claims

1. Use of TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines.

2. Use of the TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines according to claim 1, characterized in that: The TGF-β1 gene knockout tumor cells need to be inactivated.

3. Use of the TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines according to claim 2, characterized in that: The inactivation method is irradiation inactivation.

4. The use of TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines according to claim 3, characterized in that: The irradiation is carried out by X-ray irradiation, and the irradiation dose is 60Gy for a single irradiation.

5. Use of the TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines according to claim 1, characterized in that: The tumor cell vaccine is a preventive tumor cell vaccine.

6. Use of the TGF-β1 gene knockout tumor cells in the preparation of tumor cell vaccines according to claim 1, characterized in that: The tumor cells include at least one of melanoma, colorectal cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, gastric cancer, bile duct cancer, gallbladder cancer, esophageal cancer, kidney cancer, pancreatic cancer, prostate cancer or glioblastoma.

7. Use of TGF-β1 gene knockout tumor cells combined with immune adjuvants in the preparation of tumor cell vaccines.

8. Use of TGF-β1 gene knockout tumor cells combined with immune adjuvants in the preparation of tumor cell vaccines according to claim 7, characterized in that: The immune adjuvant is Poly I:C immune adjuvant.

9. Use of TGF-β1 gene knockout tumor cells combined with immune adjuvant in the preparation of tumor cell vaccine according to claim 7, characterized in that: The ratio of the TGF-β1 gene knockout tumor cells to the immune adjuvant is 1×10 6 The cells were mixed with 25 μg Poly I:C.

10. Use of the TGF-β1 gene knockout tumor cells combined with an immune adjuvant in the preparation of a tumor cell vaccine according to claim 7, characterized in that: The tumor cell vaccine is a preventive or therapeutic tumor cell vaccine.